Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants

Bone Marrow Transplantation

Volumn 48, Issue 1, 2013, Pages 99-104

  Goldberg, J D ^a,b   Zheng, J ^a   Castro Malaspina, H ^a,b   Jakubowski, A A ^a,b   Heller, G ^a   Van Den Brink, M R M ^b   Perales, M A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Allogeneic transplant; Mucositis; Palifermin

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE TRIPHOSPHATE; MELPHALAN; PALIFERMIN; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; EVENT FREE SURVIVAL; EYELID EDEMA; FEMALE; FOOT EDEMA; GRAFT FAILURE; HAND EDEMA; HEMATOLOGIC MALIGNANCY; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MYELOABLATIVE CONDITIONING; ORAL DISCOLORATION; ORAL HYPERPLASIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PATIENT CONTROLLED ANALGESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RASH; RETROSPECTIVE STUDY; SURVIVAL TIME; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; FIBROBLAST GROWTH FACTOR 7; FOLLOW-UP STUDIES; GASTROINTESTINAL TRACT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUCOSITIS; NEW YORK CITY; PROTECTIVE AGENTS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 84872123561     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.115     Document Type: Article

References (27)

1. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383-388. (Pubitemid 40542931)
2. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993; 72: 1612-1617. (Pubitemid 23249287)
3. McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 1993; 20: 1493-1502.
4. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19: 2201-2205. (Pubitemid 32372323)
5. Rubin JS, Osada H, Finch PW, Taylor WG, Rudikoff S, Aaronson SA. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci USA 1989; 86: 802-806. (Pubitemid 19056244)
6. Werner S, Peters KG, Longaker MT, Fuller-Pace F, Banda MJ, Williams LT. Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc Natl Acad Sci USA 1992; 89: 6896-6900.
7. Dorr W, Kummermehr J. Increased radiation tolerance of mouse tongue epithelium after local conditioning. Int J Radiat Biol 1992; 61: 369-379.
8. Dorr W, Noack R, Spekl K, Farrell CL. Modification of oral mucositis by keratinocyte growth factor: single radiation exposure. Int J Radiat Biol 2001; 77: 341-347. (Pubitemid 32217278)
9. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58: 933-939. (Pubitemid 28182461)
10. Farrell CL, Rex KL, Kaufman SA, Dipalma CR, Chen JN, Scully S et al. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol 1999; 75: 609-620. (Pubitemid 29243139)
11. Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003; 21: 1452-1458. (Pubitemid 46594095)
12. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-2598. (Pubitemid 39628580)
13. Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108: 3216-3222.
14. Langner S, Staber P, Schub N, Gramatzki M, Grothe W, Behre G et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008; 42: 275-279.
15. Nasilowska-Adamska B, Rzepecki P, Manko J, Czyz A, Markiewicz M, Federowicz I et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 2007; 40: 983-988. (Pubitemid 350048198)
16. Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant 2011; 17: 1343-1351.
17. Ho VT. Ex vivo T cell depletion of allogeneic PBSC as acute and chronic GVHD prophylaxis after myeloablative HCT: time to reconsider? Biol Blood Marrow Transplant 2011; 17: 1112-1113.
18. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant 2008; 14: 458-468. (Pubitemid 351372752)
19. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, Mackinnon S, Boulad F et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083-1090. (Pubitemid 28078314)
20. Jakubowski AA, Small TN, Young JW, Kernan NA, Castro-Malaspina H, Hsu KC et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood 2007; 110: 4552-4559. (Pubitemid 351377823)
21. Shank B, Chu FC, Dinsmore R, Kapoor N, Kirkpatrick D, Teitelbaum H et al. Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Phys 1983; 9: 1607-1611. (Pubitemid 14246659)
22. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. British journal of haematology 1997; 97: 855-864. (Pubitemid 27321388)
23. Sullivan KM. Chronic graft-versus-host disease. Cancer Treat Res 1990; 50: 79-98.
24. Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graftversus-host disease. Blood 1999; 94: 825-831. (Pubitemid 29323898)
25. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 1998; 92: 3960-3967. (Pubitemid 28525223)
26. Le QT, Kim HE, Schneider CJ, Murakozy G, Skladowski K, Reinisch S et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol 2011; 29: 2808-2814.
27. Henke M, Alfonsi M, Foa P, Giralt J, Bardet E, Cerezo L et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol 2011; 29: 2815-2820.